Tyler Van Buren analyst TD COWEN

Currently out of the existing stock ratings of Tyler Van Buren, 201 are a BUY (80.08%), 45 are a HOLD (17.93%), 5 are a SELL (1.99%).

Tyler Van Buren

Work Performance Price Targets & Ratings Chart

Analyst Tyler Van Buren works at TD COWEN with a stock forecast success ratio of 36.86% fulfilled within 132.63 days on average.

Tyler Van Buren’s has documented 485 price targets and ratings displayed on 48 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 25-Jan-2024.

Wall Street Analyst Tyler Van Buren

Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 2/24/2021. The price target of $19.43 was fulfilled within 2 days with a profit of $2.64 (15.72%) receiving and performance score of 78.62.

Average potential price target upside

ADVM Adverum Biotechnologies AGIO Agios Pharm ALLO Allogene Therapeutics APTO Aptose Biosciences BGNE BeiGene Ltd BHVN Biohaven Pharmaceutical Holding Co Ltd BLUE Bluebird bio GILD Gilead Sciences GOSS Gossamer Bio HARP Harpoon Therapeutics INCY yte IONS Ionis Pharmaceuticals MRNA Moderna MRTX Mirati Ther NKTR Nektar Therapeutics OTIC Otonomy RCKT Rocket Pharmaceuticals SRPT Sarepta Therapeutics AERI Aerie Pharmaceuticals . ARVN Arvinas REGN Regeneron Pharmaceuticals TBPH Theravance Biopharma BBIO BridgeBio Pharma BCRX BioCryst Pharmaceuticals CRNX Crinetics Pharmaceuticals FATE Fate Therapeutics KURA Kura Oncology MGTX MeiraGTx Holdings PLC NRIX Nurix Therapeutics  OVID Ovid Therapeutics OYST Oyster Point Pharma PRAX Praxis Precision Medicines  PTE Polarityte CRSP Crispr Therapeutics AG NEOS Neos Therapeutics TPTX Turning Point Therapeutics CBAY Cymabay Therapeu CBIO Catalyst Biosciences LPTX Leap Therapeutics ALGS Aligos Therapeutics  DCPH Deciphera Pharmaceuticals LLC PSTX Poseida Therapeutics EIDX Eidos Therapeutics IMCR Immunocore Holdings Ltd NLTX Neoleukin Therapeutics TYRA Tyra Biosciences RETA Reata Pharmaceuticals TVTX Travere Therapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

4

$-8.58 (-68.20%)

2

2 months 12 days ago

4/4 (100%)

$1.5 (60.00%)

279

Buy

6

$4.05 (207.69%)

4

7 months 13 days ago

4/7 (57.14%)

$4.22 (237.08%)

196

Buy

4

$-8.58 (-68.20%)

2

8 months 7 days ago

4/4 (100%)

$2.11 (111.64%)

432

Hold

3

$-9.58 (-76.15%)

6

1 years 5 months 7 days ago

3/4 (75%)

$2.23 (289.61%)

528

Hold

2

$-10.58 (-84.10%)

5

2 years 8 months 26 days ago

3/3 (100%)

$-0.36 (-15.25%)

397

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Tyler Van Buren is most bullish on?

Potential upside of $81.52 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is Tyler Van Buren is most reserved on?

Potential downside of -$34.09 has been obtained for CRSP (CRISPR THERAPEUTICS AG)

What Year was the first public recommendation made by Tyler Van Buren?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?